SCHEMBL3764191

SCHEMBL3764191

Cc1n[nH]c2ccnc(Nc3ccc(Cl)cc3Cl)c12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LRRK2 Q5S007 1/20 0.45
GRM4 Q14833 3/20 0.44
MAPK1 P28482 1/20 0.44
PIK3CG P48736 5/20 0.43
PIK3CA P42336 4/20 0.40
PIK3CB P42338 4/20 0.40
SRC P12931 2/20 0.40
THRB P10828 1/20 0.40
PDGFRB P09619 1/20 0.39
DYRK1A Q13627 2/20 0.37
DYRK1B Q9Y463 2/20 0.37
IGF1R P08069 1/20 0.37
DYRK3 O43781 1/20 0.37
CDK1 P06493 1/20 0.37
CDK4 P11802 1/20 0.37
CDK2 P24941 1/20 0.37
CLK1 P49759 1/20 0.37
CLK2 P49760 1/20 0.37
GSK3A P49840 1/20 0.37
GSK3B P49841 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13060923 0.90 LRRK2 (0.41) LRRK2GRM4PIK3CGSRC
SCHEMBL3766773 0.84 EGFR (0.52) LRRK2GRM4IGF1RCDK2
SCHEMBL3775370 0.84 LRRK2 (0.63) LRRK2GRM4CDK2
SCHEMBL3771231 0.82 GRM4 (0.56) GRM4SRCPDGFRBCDK1
SCHEMBL3762265 0.81 GRM4 (0.54) LRRK2GRM4
SCHEMBL3775310 0.80 GRM4 (0.57) LRRK2GRM4
SCHEMBL3775900 0.78 GRM4 (0.48) LRRK2GRM4CDK1CDK2
SCHEMBL3774577 0.76 LRRK2 (0.47) LRRK2GRM4CDK2
SCHEMBL3771732 0.76 LRRK2 (0.39) LRRK2GRM4
SCHEMBL3766517 0.75 LRRK2 (0.36) LRRK2GRM4MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
US-20170320870-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2017-11-09 US disclosed
EP-2408772-B1 COMPOUNDS MEDICAL RES COUNCIL TECHNOLOGY (GB) 2015-07-01 EP disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed
US-20100317646-A1 COMPOUNDS MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) 2010-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320870-A1 COMPOUNDS CBR3, CNR1, HCAR3 LRRK2 2309/4885GRM4 1109/4885MAPK1 2637/4885
US-20100317646-A1 COMPOUNDS CBR3, CNR1, HCAR3 LRRK2 2208/4885GRM4 1107/4885MAPK1 2749/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.